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Background: Variation in care is common in medical practice. Reducing variation in care is shown to improve quality and increase favorable 
outcomes in chronic diseases. We sought to identify factors associated with variation in care in children with newly diagnosed Crohn’s disease 
(CD).
Methods: Prospectively collected data from a 28-site multicenter inception CD cohort were analyzed for variations in diagnostic modalities, 
treatment, and follow-up monitoring practices, along with complicated disease outcomes over 3 years in 1046 children. Generalized linear mixed 
effects models were used to investigate the intercenter variations in each outcome variable.
Results: The mean age at diagnosis was 12 years, and 25.9% were nonwhite. The number of participants ranged from 5 to 112 per site. No vari-
ation existed in the initial diagnostic approach. When medication exposure was analyzed, steroid exposure varied from 28.6% to 96.9% (P < 0.01) 
within 90 days, but variation was not significant over a 3-year period (P = 0.13). Early anti–tumor necrosis factor (anti-TNF) exposure (within 
90 days) varied from 2.1% to 65.7% (P < 0.01), but variation was not significant over a 3-year period (P > 0.99). Use of immunomodulators (IMs) 
varied among centers both within 90 days (P < 0.01) and during 3 years of follow-up (P < 0.01). A significant variation was seen at the geographic 
level with follow-up small bowel imaging and colonoscopy surveillance after initial therapy.
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Conclusions: Intercenter variation in care was seen with the initial use of steroids and anti-TNF, but there was no difference in total 3-year expo-
sure to these drugs. Variation in the initiation and long-term use of IMs was significant among sites, but further research with objective measures 
is needed to explain this variation of care. Small bowel imaging or repeat colonoscopy in CD patients was not uniformly performed across sites. 
As our data show the widespread existence of variation in care and disease monitoring at geographic levels among pediatric CD patients, future 
implementation of various practice strategies may help reduce the variation in care.
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INTRODUCTION
Crohn’s disease (CD) is one of the chronic disorders fre-
quently seen in pediatric gastroenterology practices in North 
America. As CD is not a reportable disease, it is difficult to estimate 
the prevalence of CD among children accurately. However, the ex-
trapolation of insurance claims data and other population-based 
regional data estimate that about 80,000 children currently carry 
a diagnosis of CD in the United States.1, 2 Although many treat-
ment modalities are employed by practicing gastroenterologists, 
a limited number of medications (only 2)  are Food and Drug 
Administration (FDA) approved for CD in children.3–6 There is 
a paucity of standardized practice guidelines, and variation in 
care of children with CD is common.7–11 Variation in care with 
respect to diagnostic approaches, treatment choices (including the 
use of biologics), and disease monitoring is further influenced by 
physician style, costs, insurance status, and patients’ preferences/
expectations.7, 8, 12–15 All these factors could collectively contribute 
to variation in care and the management of pediatric CD.
Reducing variation in care and adhering to evidence-based 
practice guidelines has improved the outcomes of children with 
chronic diseases.12 For instance, outcomes for chronic, often 
fatal, medical conditions, including cystic fibrosis and child-
hood cancers have drastically improved by strictly adhering 
to protocolized clinical trial–based guidelines.13 A  systematic 
approach to examine the variation of care among CD was 
undertaken by Kappelman and colleagues a decade ago.8 Using 
a prospective pediatric inflammatory bowel disease (IBD) reg-
istry, this study examined the practice variation among 311 
children with CD enrolled between 2002 and 2005 at 10 cen-
ters in North America. Widespread intercenter variation in the 
management of newly diagnosed children with CD was seen at 
multiple levels. A quality improvement project, Improve Care 
Now (ICN), was launched at a later time point, and 1 of the 
objectives of the initiative was to reduce the variation of care 
among children with CD.16–18
We have an unprecedented opportunity to revisit the 
variation of care and management differences among newly 
diagnosed CD in North America after the initial report from 
Kappelman et al.8 We sought to use the Risk Stratification and 
Identification of Immunogenic and Microbial Markers of Rapid 
Disease Progression in Children with Crohn’s disease (RISK) co-
hort for this purpose. This inception cohort study was launched 
in 2008 and recruited 1046 newly diagnosed treatment-naïve 
CD patients from 28 centers. This cohort involved prospective, 
standardized 6-month data collection, and all participants were 
followed for a minimum of 3 years where the treatment decision 
was left to the clinicians without protocolized standard regimes. 
The objectives of the current study were to (1) assess intercenter 
variation in diagnostic testing, (2) examine intercenter variation 
in treatment approaches, and (3) evaluate whether geography of 
the site is associated with variation.
METHODS
Study Population and Centers
The Crohn’s and Colitis Foundation supported the RISK 
inception cohort study, which enrolled 1046 pediatric (<18 years 
old) patients diagnosed with CD (nonstricturing, nonpene-
trating) from 28 North American centers (including 3 from 
Canada) from November 2008 to June 2012 (ClinicalTrials.gov 
Identifier: NCT00790543). Geographic regions were divided 
into the Midwest, Northeast, South, and West according to US 
Census Bureau geographic atlas regions published in 2010.19 We 
have included 3 Canadian sites into the Northeast category as 
all 3 Canadian sites were situated along Eastern Canada.
Ethical Considerations
The institutional review board of each participating 
site reviewed and approved the study. Informed consent was 
obtained from parents/guardians or patients appropriately. 
Patients gave written assent where appropriate.
Diagnosis of CD, UC, and IBDU
Initial diagnosis was made by the center investigator, and 
the classification for disease type and location was done after 
reviewing the predetermined criteria.20 Disease behavior, loca-
tion, and the presence of perianal disease were defined based on 
the Montreal classification system.21, 22 Stricturing disease (B2) 
was defined as persistent luminal narrowing with prestenotic 
dilation observed by contrast small bowel imaging. Internal 
penetrating disease (B3) was defined as an intra-abdominal fist-
ulizing disease resulting in an intra-abdominal or pelvic abscess 
or fistula to an adjacent organ, excluding the vagina or peri-
anal region. B1 refers to uncomplicated inflammatory disease. 
Surgery is classified as those who underwent luminal surgery 
any time during the 3-year follow-up. Indications for surgery 
include strictures, bowel obstruction, or internal penetrating 
disease that did not respond to percutaneous drainage.
Initial Management
Patients were not managed by standardized protocols, 
but instead at the discretion of their local gastroenterologist. 
Early use of steroids, immunomodulators (IMs), or early anti–
tumor necrosis factor (anti-TNF) exposure was defined by initi-
ation of therapy within 90 days of diagnosis. Ever exposure was 
defined as exposure to IMs or anti-TNFs at any time during the 
3 years of follow-up after diagnosis.
Disease Monitoring
Patients were followed longitudinally according to either 
individual center protocols or physician recommendation. 
Computerized tomography (CT), magnetic resonance enterog-
raphy (MRE), small bowel followthrough (SBFT), and video 
capsule endoscopy were considered appropriate imaging for 
monitoring. No other type of imaging, including nuclear scan 
or ultrasound, was included.
Statistics
Frequencies and percentages were computed at the center 
level with site IDs de-identified and compared for center char-
acteristics. Funnel plots were used to illustrate the intercenter 
variability of each outcome. The overall percentage is repre-
sented by a center line in each funnel plot. Upper and lower 
confidence limits at 95% (2 SDs) and 99.9% (3 SDs) are plotted 
against the center line and form the funnel, which provides a 
graphical display of permitted center-specific differences from 
the overall by random variation in patient characteristics and 
volume across the centers. The centers outside the funnel rep-
resent institutional practices that may be significantly different 
from the overall average. To analytically investigate the inter-
center variations in each outcome, we used generalized linear 
mixed effects models.23 Patient-level factors (age at diagnosis, 
sex, race, and Physician Global Assessment [PGA] at diagnosis) 
and different follow-up times were controlled as the covariates 
and an offset, respectively, in all analyses. We assessed the dif-
ference in the average practices by center characteristic (geo-
graphic region), significance of intercenter variabilities overall, 
and difference in the intercenter variabilities within centers 
sharing the same center characteristics after accounting for 
difference and variations by patient-level factor. We used like-
lihood ratio tests at a significance level of 0.05 to address the 
latter 2 questions. The F-test was used to determine the signifi-
cance of the difference in average practices by center character-
istic (geographic region).
RESULTS
Demographics of the Centers
Out of the 28 centers that participated in the inception 
cohort study from the United States (n  =  25) and Canada 
(n = 3), the number of subjects with CD (n = 1046) per center 
ranged from 5 to 112 (median, 31; mean, 37). In the United 
States, there were 12 centers from the Northeast, 5 from the 
Midwest, 7 from the South, and 4 from the West. The mean 
age of the 1046 patients (range) was 12.3 (2–18) years (Table 1). 
Subjects were mostly white (74.1%, ranging from 30% to 97.2% 
by center) and male (61.1%). There were no differences with 
sex or age of onset among centers. According to the Montreal 
classification, small bowel disease (L1) was seen in 22%, colonic 
disease (L2) was seen in 22%, and ileocolonic disease (L3) was 
seen 54%. The sex distribution, race, age of onset of CD, dis-
ease location, and presence of perianal disease at diagnosis were 
similar to previously published large cohorts in pediatrics.24, 25
Initial Diagnostic Approach
Colonoscopy was performed on 1040 (99.4%) of  1046 
patients at baseline. Of  these colonoscopies, the ileum was 
intubated 93.1% of  the time (974), with no significant vari-
ation existing among centers after accounting for patient-
level factors (range, 57.1%–100%; P  =  0.95) (Table  2). One 
thousand twenty-three subjects (97.8%) also had an upper 
endoscopy at baseline. However, only 778 subjects (72.4%) 
(Supplementary Table 1) had small bowel imaging (MRE, CT, 
small bowel followthrough, or video capsule endoscopy), and 
the site-specific percentages of  subjects’ small bowel imaging 
ranged from 20% to 97.9%, exhibiting a significant variation 
(P < 0.01) (Table 2).
Initial Treatment Approach
Medication data were analyzed based on 2 criteria: expo-
sure within 90  days after diagnosis or ever exposed during 
the entire 3-year follow-up period. As we reported earlier,26 a 
90-day cut-point for early introduction was chosen arbitrarily.
Reported medications included 5 amino-salicylic acid (5-ASA),
corticosteroids, immunomodulators (azathioprine [AZA]/6
mercaptopurine [6-MP], methotrexate), and anti-TNF drugs
(infliximab or adalimumab).
Corticosteroids
A significant variation was seen in steroid exposure 
within 90 days, which varied from 28.6% to 96.9% among cen-
ters, with an overall usage of 68.2% (P < 0.01). However, no 
significant variation was found in ever corticosteroid exposure 
during 3-year follow-up with the center-specific exposures rang-
ing from 47.1% to 100% (P = 0.13) (Table 2 and Fig. 1A and B). 
This indicates that variation existed during the initial treatment 
period with corticosteroids, but not during the later time.
5-ASA
Forty-five point two percent of patients were exposed 
to 5-ASA within 90 days (range, 0%–93.9%); 47% of patients 
were reported to be on 5-ASA during the entire follow-up 
(range, 0%–93.9%). Significant intercenter variation was noted 
(P < 0.01) (Supplementary Table 2), but variation among sites 
sharing the same geographic region was found to be similar 
(P = not significant). The average percentage of 5-ASA use did 
not differ among different geographic regions (Supplementary 
Table 3).
Immunomodulators
Unlike corticosteroids, there was a significant intercenter 
variation in both 90-day and 3-year exposure to IM. (Table 2 and 
Fig. 1C and D). In our study, 50.1% of the patients received IM 
within the first 90 days of diagnosis. There was a wide range of 
variation among centers (range, 0%–91.4%; P < 0.01) (Table 2 and 
Fig. 1C). This variation was also seen with ever exposure to IM 
during the 3-year follow-up (range, 24.4%–100%, with an overall 
usage of 73.7%; P < 0.01) (Table 2 and Fig. 1D). Furthermore, 
when centers were grouped by geographic region, intercenter var-
iation was greater within certain geographic regions than others 
(P = 0.01 for the exposure within 90 days after diagnosis; P = 0.02 
for the exposure any time during follow-up) (Table 2). Centers in 
the Midwest displayed the highest geographic regional average 
usage (70.8% early and 88.3% ever) with the least variation in IM 
treatment practice among themselves. Northeast centers have the 
lowest geographic regional average use of early (39.2%) and cu-
mulative (66.5%) IM treatment with the biggest variation among 
themselves (Fig. 1C and D; Supplementary Table 4).
Overall use of 6MP/AZA (range) was 53.3% (9.3%–
89.6%), and methotrexate use was 38.8% (0%–87.5%) 
TABLE 1. Demographic Characteristics of Children With Crohn’s Disease by Site Characteristics
Center-Level Characteristics Age, Mean (SD), y Male, No. (%) Nonwhite, No. (%)
Moderate/Severe Disease Activity at 
Diagnosis According to PGA, No. (%)
Overall - 12.3 (3.1) 640 (61.1) 271 (25.9) 682 (65.2)
Site 1 13.0 (3.6) 7 (50.0) 2 (14.3) 11 (78.6)
2 12.3 (3.1) 19 (51.3) 7 (18.9) 16 (43.2)
3 12.9 (2.8) 20 (66.6) 21 (70.0) 27 (90.0)
4 11.7 (2.9) 36 (61.0) 13 (22.0) 37 (62.7)
5 12.8 (3.1) 76 (67.8) 40 (35.7) 82 (73.2)
6 12.1 (3.1) 13 (37.1) 9 (25.7) 30 (85.7)
7 12.1 (3.0) 62 (60.7) 16 (15.7) 69 (67.6)
8 11.6 (3.2) 9 (52.9) 7 (41.1) 15 (88.2)
9 12.1 (2.5) 6 (75.0) 3 (37.5) 5 (62.5)
10 12.1 (3.0) 29 (65.9) 5 (11.3) 26 (59.1)
11 12.4 (3.0) 36 (65.4) 30 (54.5) 36 (65.4)
12 12.0 (3.5) 6 (85.7) 1 (14.2) 4 (57.1)
13 12.6 (3.2) 58 (64.4) 28 (31.1) 43 (47.8)
14 12.2 (3.1) 17 (70.8) 1 (4.1) 19 (79.2)
15 11.6 (4.2) 19 (57.6) 11 (33.3) 16 (48.5)
16 14.3 (2.2) 16 (69.6) 3 (13.0) 13 (56.5)
17 11.5 (3.2) 18 (51.4) 1 (2.8) 34 (97.1)
18 12.3 (3.3) 54 (62.8) 20 (23.2) 73 (84.9)
19 12.7 (3.0) 10 (55.6) 6 (33.3) 5 (27.8)
20 12.8 (2.2) 2 (40.0) 1 (20.0) 3 (100.0)
21 11.8 (3.0) 29 (60.4) 7 (14.6) 13 (27.1)
22 11.7 (3.6) 19 (63.3) 13 (43.3) 19 (63.3)
23 12.8 (3.2) 21 (65.6) 10 (31.2) 29 (90.6)
24 11.3 (3.4) 10 (55.6) 7 (38.9) 7 (38.9)
25 13.1 (1.3) 3 (42.8) 1 (14.3) 4 (57.1)
26 11.6 (3.2) 13 (54.1) 4 (16.7) 17 (70.8)
27 11.9 (2.4) 22 (62.8) 3 (8.6) 23 (65.7)
28 11.7 (3.3) 10 (55.6) 1 (5.6) 6 (33.3)
Geographic
region
Midwest 11.9 (3.0) 146 (60.8) 41 (17.1) 140 (58.3)
Northeast 12.4 (3.2) 342 (63.0) 135 (24.9) 351 (64.6)
South 12.7 (3.0) 106 (63.1) 75 (44.6) 107 (63.7)
West 11.8 (3.0) 46 (48.4) 20 (21.0) 84 (88.4)
(Supplementary Table  5). The use of 6MP/AZA differed be-
tween geographic regions (P = 0.001), where the Midwest region 
had the higher percentage (81.7%) of thiopurine use compared 
with the other 3 regions (Supplementary Table 6).
Anti-TNF
A significant intercenter variation in use of anti-TNF 
during the first 90 days was seen (range, 2.1%–65.7%; P < 0.01), 
but the variability did not differ significantly by center group 
characteristics or geographic region (P  =  0.65) (Table  2). 
However, when ever exposed to anti-TNF during the 3 years 
of follow-up is considered, centers depicted more similarity to 
each other, with an overall percentage use of 65.9% (P > 0.99) 
(Table 2 and Fig. 1E and F).
Despite similar variation within each geographic region, 
the average regional practice of early anti-TNF use was signifi-
cantly different (P = 0.025, 0.023, and 0.034 for within 90 days, 
within 6  months, and within 1  year, respectively) (Table  3). 
Centers in the South (36.9%) and West (42.1%) regions showed 
earlier use of anti-TNF compared with centers in the Midwest 
(14.6%) and Northeast (18.4%) regions. A similar pattern was 
observed during up to 1 year of anti-TNF use, but these differ-
ences disappeared by 3 years (P = 0.54) (Table 3) as the centers 
in the Northeast and Midwest started to use more anti-TNF 
during the second and third years of follow-up (Supplementary 
Table  7). Infliximab was the most used anti-TNF (range, 
21.6%–85.7%), whereas adalimumab use was reported to be in 
the range of 2.9% to 60%.
Still, there was a delay in initiating either IM or anti-
TNF early. When within 90 days of drug exposure was consid-
ered, 32.5% of the subjects did not receive any IM or biologics, 
whereas 45% received IM only, 17.4% received anti-TNF only, 
and 5.3% of patients received a combination with both IM and 
anti-TNF (Supplementary Table 8).
Combination therapy
There was a significant intercenter variation in the early 
selection of IM and anti-TNF (P  <  0.01). The use of early 
IM alone was seen in 45% (range, 0%–84.4%), whereas anti-
TNF alone was 17.4% (range, 0%–57.1%). When considering 
TABLE 2. Likelihood Ratio Test of Overall Intercenter Variability in Clinical Practice in Pediatric Crohn’s Disease and 
Variations Between Centers Sharing Different Characteristics
Significance of Intercenter 
Variability, Pa
Significance of Difference in the 
Intercenter Variabilities by  
Geographic Region, Pb
Baseline endoscopy >0.99 >0.99
Baseline small bowel imaging <0.01 <0.01
Baseline upper GI endoscopy >0.99 >0.99
Baseline colonoscopy up to terminal ileum <0.01 0.46
Follow-up endoscopy <0.01 0.51
Follow-up small bowel imaging <0.01 0.28
Follow-up upper GI endoscopy <0.01 0.13
Follow-up with either endoscopy or small bowel imaging 0.26 0.75
Steroid exposure within 90 d <0.01 0.03
Steroid exposure ever used in 3 y 0.20 0.39
5-ASA exposure within 90 d <0.01 0.25
5-ASA exposure ever used in 3 y <0.01 0.22
Immunomodulator within 90 d <0.01 <0.01
Immunomodulator ever used in 3 y <0.01 0.01
Anti-TNF within 90 d <0.01 0.65
Anti-TNF within 183 d <0.01 0.59
Anti-TNF within 365 d <0.01 0.60
Anti-TNF ever used in 3 y >0.99 0.95
Neither immunomodulator nor anti-TNF within 90 d <0.01 0.12
Neither immunomodulator nor anti-TNF ever used in 3 y <0.01 0.44
aThe P values in this column are from the likelihood ratio tests comparing a no-intercenter variation model with a random intercept model that allows site-to-site variation. In all 
models, patient-level factors (age at diagnosis, Physician Global Assessment at diagnosis, sex, and race) are controlled for.
bThese P values are from the likelihood ratio tests comparing the random intercept model with the models that further accommodate the difference in the intercenter variability by 






































































































































































































































































FIGURE 1. A, Percentage of patients who received steroids within 90 days of diagnosis. B, Percentage of patients who received steroids during 
the entire period of study. C, Percentage of patients who received immunomodulators within 90 days of diagnosis. D, Percentage of patients who 
received immunomodulators during the entire period of the study. E, Percentage of patients who received anti-TNF within 90 days of diagnosis. F, 
Percentage of patients who received anti-TNF during the entire period of the study.
the entire 3-year period of treatment, 50.5% (range, 20.9%–
77.8%) of patients had combination therapy with both IM 
and anti-TNF, whereas 15.4% (range, 0%–71.4%) of patients 
had only anti-TNF and 23.2% (range, 0%–42.9%) had IM only 
(Supplementary Table  8). The average percentage of those 
using neither IM nor anti-TNF was not equal among geo-
graphic regions (P = 0.03 and 0.02 for the early and cumula-
tive, respectively). The Northeast has the highest percentage of 
using neither within 90 days (46.2%) or during the entire fol-
low-up (16.4%) (Table 4).
Disease Monitoring With Follow-up Imaging and 
Endoscopies
As this is an observational cohort without a specified fol-
low-up protocol in place, follow-up visits or disease monitoring 
imaging/endoscopies were performed solely at the discretion 
of the treating clinician. During the 3-year follow-up period, 
50% (range, 12.5%–82.6%) of patients underwent repeat 
upper gastrointestinal (GI) endoscopic evaluation and 64.2% 
(range, 38.9%–100%) had small bowel imaging (abdominal CT, 
abdominal/pelvic MRE, or video capsule endoscopy). Taken 
together, only 79.4% of patients had either repeat colonoscopy 
or imaging during their 3-year follow-up period, leaving 20.6% 
of patients without any repeat evaluation (Supplementary 
Table 1). There was no significant intercenter variation among 
centers (P = 0.29) or geographic regions (P = 0.90) with regard 
to repeat endoscopic or imaging evaluation (Table 2).
Disease Outcome Variation During 3-Year 
Follow-up
Overall there were 145 stricturing (13.9%, ranging from 
0% to 28.6% per center) and 60 penetrating (5.7%, ranging from 
0% to 12.5% per center) complications, with 121 (11.6%, rang-
ing from 0% to 42.9% per center) requiring resective surgeries 
(Supplementary Table 9). Neither complicated disease nor sur-
gery rate varied among the participating centers. The event rate 
of only 11.6% did not allow us to assess if  variation in care 
influenced the complicated outcome. Complications are evolv-
ing, and dynamic events in CD and longer follow-up with more 
TABLE 4. Intercenter Variation in IM and/or Anti-TNF Use by Geographic Region
Within 90 d of Diagnosis, No. (%) Ever Used in 3 y, No. (%)
Category No. Neither IM Only
Anti-TNF 
Only Both Neither IM Only
Anti-TNF 
Only Both




 Midwest 240 42 (17.5) 163 (67.9) 28 (11.7) 7 (2.9) 10 (4.2) 90 (37.5) 18 (7.5) 122 (50.8)
 Northeast 543 251 (46.2) 192 (35.4) 79 (14.5) 21 (3.9) 89 (16.4) 102 (18.8) 93 (17.1) 259 (47.7)
 South 168 33 (19.6) 73 (43.5) 52 (31.0) 10 (6) 9 (5.4) 31 (18.5) 41 (24.4) 87 (51.8)
 West 95 14 (14.7) 41 (43.2) 23 (24.2) 17 (17.9) 6 (6.3) 20 (21.1) 9 (9.5) 60 (63.2)
aThe P values are from the models with the outcome defined as binary variables with “neither IM nor anti-TNF within 90 days” = 1 and “neither IM nor anti-TNF during the 
entire follow-up” = 1.
TABLE  3. Difference in Average Practice by Center-
Level Characteristics
Significance of Difference in  
Average Practice by  
Geographic Region, Pa
Baseline colonoscopy 0.96
Baseline small bowel imaging 0.17
Baseline upper GI endoscopy 0.98




Follow-up small bowel imaging 0.76
Follow-up upper GI endoscopy 0.77
Follow-up with either colonoscopy 
or small bowel imaging
0.60
Steroid exposure within 90 d 0.36
Steroid exposure ever used in 3 y 0.58
Immunomodulator within 90 d 0.11
Immunomodulator ever used in 3 y 0.36
Anti-TNF within 90 d 0.03
Anti-TNF within 183 d 0.02
Anti-TNF within 365 d 0.03
Anti-TNF ever used in 3 y 0.54
Neither immunomodulator nor 
 anti-TNF within 90 d
0.03
Neither immunomodulator nor 
anti-TNF ever used in 3 y
0.02
aThe P values are from the GLMM F-test, which determines the significance of differ-
ence in the average practices by the corresponding center characteristic.
events of complication are necessary to evaluate if  variation in 
care influences the outcome or natural history of CD.
DISCUSSION
It has been established that variation in care exists in the 
diagnosis and management of IBD in pediatrics.8–11 Over the 
last 2 decades, practice guidelines have been published in both 
pediatric and adult IBD.27–31 There have been several initiatives 
to decrease variation in IBD care in North America, including 
quality improvement projects9, 32–35 and multicenter collabora-
tive studies.16, 36 Previous publications addressing variation in 
care were limited by a small number of subjects, and they did 
not include the variation among geographic regions or anti-
TNF in the treatment paradigm.8 Furthermore, there have been 
only a few large studies addressing the variation of care in pedi-
atric IBD since 2007.9, 10, 35 Our 28-center, 1046-subject inception 
cohort study with prospective, standardized 6-month to 3-year 
follow-up and 3-year disease course data offers an unprece-
dented opportunity for reevaluation of care variance. Although 
there has been a decrease in variation of certain aspects of care 
including colonoscopy/ileoscopy in the diagnostic approach to 
IBD, we continue to see a large variation in care with regard to 
treatment and disease monitoring.
A study from the United Kingdom in 2003 by Sawczenko 
et al. concluded that patients receive different care according to 
their geographic region and choice of specialist category (pedi-
atric or adult gastroenterologist vs adult services).7 This study 
showed that children had less chance to undergo colonoscopy 
and more chance to undergo sigmoidoscopy if  they were receiv-
ing care from adult services. No further studies have been pub-
lished in the United Kingdom on this subject since then, and 
the practices have likely changed in the United Kingdom. Our 
study clearly shows that all the centers in North America now 
have universally adopted full colonoscopy rather than sigmoid-
oscopy in the diagnosis of pediatric IBD. Although there was 
a little variation with the initial diagnostic approach, follow-up 
endoscopies either for disease reevaluation or surveillance 
varied significantly. This may have been due to patient prefer-
ences, physician choices, availability of institutional resources, 
or cost-related issues.7, 8 Emerging data from recent IBD liter-
ature suggest that tight control of inflammation using thera-
peutic drug monitoring and endoscopic evaluation can result 
in better mucosal healing outcomes.37–40 Many pediatric gastro-
enterology centers that participated in this study now consider 
mucosal healing to be one of the main goals of therapy, rather 
than symptom improvement. There still are no reliable surro-
gate markers for mucosal healing, and hence repeat endoscopic 
evaluation is considered one of the best ways to assess mucosal 
healing, particularly in colonic disease.41 However, possible bar-
riers to such an approach include cost, insurance approval, and 
patient acceptance. Future implementation of various practice 
strategies may help reduce the variation in care.42
Even though corticosteroids and IM have been the main-
stay of treatment in IBD care among children, we noted an 
increasing trend in the early use of anti-TNFs, particularly 
within 90 days of diagnosis.8, 26 Remarkably, almost half  of all 
patients received 5-ASA despite the lack of published evidence 
of efficacy in adults or children with Crohn’s disease; we have 
excluded it in the final analysis.43–45 Our study demonstrates 
significant intercenter variation in adopting early anti-TNF 
use. We speculate that payer/insurance preferences,15 physician 
expertise, and patients’ preferences for oral vs intravenous or 
subcutaneous drugs are possible reasons for the observed vari-
ability in treatment. Interestingly, our study shows that even 
though centers differed significantly in the early use of anti-
TNFs, they all had similar levels of usage after 1  year. The 
centers that used early anti-TNFs had less use of IMs and 
corticosteroids.
Almost a decade ago, Kappelman et al.8 evaluated varia-
tion of care in IBD management among 10 pediatric gastroin-
testinal centers across North America. Among other findings, 
he and his colleagues found statistically significant variation in 
the use of IMs among centers. Since then, several events have 
taken place in the pediatric IBD community, including the crea-
tion and implementation of the global ICN initiative to reduce 
variation in care among centers.34, 46 More than 100 pediatric 
IBD centers worldwide (97 centers in the United States, 9 in 
Belgium, 1 in Qatar, and 2 in the United Kingdom), 950 pedi-
atric gastroenterologists, and close to 30,000 children with 
IBD participated in the ICN initiative, which measures care 
for patients with both CD and UC. This has resulted in 93% 
achieving satisfactory growth, 81% achieving remission (54% 
have sustained remission), and 90% achieving satisfactory 
nutrition (https://www.improvecarenow.org/purpose-success). 
Out of 28 sites from the RISK study, 16 participated in ICN 
and 12 did not. Unfortunately, many sites joined ICN during 
the course of the RISK study, and there was not enough fol-
low-up time to make any meaningful analysis or conclusions 
regarding the impact of ICN in reducing the intercenter varia-
tion in care. Future studies will be of great interest to see if  the 
ICN initiatives have impacted variation of care in the diagnosis, 
treatment, and disease monitoring of CD.
Although our study is the largest to date, involving >1000 
subjects from a treatment-naïve inception cohort from 28 sites 
in North America, there are several limitations to our study. 
The clinical practice of pediatric IBD is constantly changing, 
and the current approach in the year 2018 may not be the same 
compared with our study, which took place between 2008 and 
2015. Recent years have seen an increasing use of methotrex-
ate compared with 6-MP (thiopurines) due to concern for 
lymphoma.47, 48 Additionally, new biologic therapies such as 
anti-adhesions and anti-IL12/23 are increasingly being used 
in pediatric gastroenterology, though they have not yet been 
approved in pediatrics, which could lead to further variation 
in care.49–51 Our study did not include any methods to check for 
medication adherence.
In conclusion, a wide variation in IBD care continues to 
exist among North American centers regarding management 
and disease monitoring. Intercenter variation in the early use 
of anti-TNFs did not persist beyond 1 year, suggesting that re-
gardless of corticosteroids and IM treatment, anti-TNFs are 
eventually used at similar rates among patients at all centers. 
Randomized control trials among pediatric IBD patients are 
needed to answer some of these questions. When randomized 
control trials are not possible or ethically justifiable, then stan-
dardized practice guidelines should be developed across many 
centers using the factors we have identified as the implementa-
tion of these evidence-based guidelines may reduce variation 
in care.
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